SWSharon WalmsleyCM, MD, FRCPCSlidesetHIVEuropean HIV Clinical Forum 2018Integrase inhibitors in specific populations- Women and those aging with HIV- Sharon Walmsley, FRCPC, MD, MSCView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2018Longer duration of virological suppression and a fully active companion drug ensure a high rate of virological control in HIV-1 infected patients switching to a dual therapy containing integrase inhibitors- Daniele ArmeniaView Slideset
PCPedro CahnMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2018Switching antiretroviral therapy to safer strategies based on intergrase inhibitors- Pedro Cahn, MD, PhDView Slideset
JAJose ArribasMDSlidesetHIVEuropean HIV Clinical Forum 2018Reduced drug regimens- What are the data?- Jose Arribas, MDView Slideset
RPRoger ParedesMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2018Resistance to integrase inhibitors- What clinicians need to know- Roger Paredes, MD, PhDView Slideset
MJMargaret JohnsonMD, FRCPSlidesetHIVEuropean HIV Clinical Forum 2018Intergrase inhibitors- What's new?-Margaret Johnson, MDView Slideset
SlidesetTokyo Hepatitis Clinical Forum 2019Evolving Treatment Paradigm and Future Landscape in HCC - Masafumi Ikeda, MDView Slideset
SlidesetTokyo Hepatitis Clinical Forum 2019Current and Future Local Therapies for Early Stage HCC -Shi-Ming Lin, MDView Slideset
SlidesetTokyo Hepatitis Clinical Forum 2019Progress in Hepatitis B Cure Research - Peter Revill, MD, PhDView Slideset
SlidesetTokyo Hepatitis Clinical Forum 2019Immunological Aspects of HBV and HCV Infection - Tatsuya Kanto, MD, PhDView Slideset
SlidesetTokyo Hepatitis Clinical Forum 2019New Anti-HBV Drugs in the Pipeline - Man-Fung Yuen, DSc, MD, PhDView Slideset
SlidesetTokyo Hepatitis Clinical Forum 2019Management of Hepatitis B Reactivation - Yasuhito Tanaka, MD, PhDView Slideset
